Search

Displaying results 2041 - 2050 of 7452 in total
  1. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. … Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.

  2. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)

  3. Drug

    Icodextrin

    go.drugbank.com/drugs/DB00702
    ApprovedInvestigational

    It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with Fabry disease that same month.[L46432,L46437]

  5. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. … Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.

  6. Drug

    Heptabarbital

    go.drugbank.com/drugs/DB01354
    Experimental

    Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.

  7. Indication

    Chronic cutaneous lupus erythematosus

    go.drugbank.com/conditions/DBCOND0013492
    Drugs: Betamethasone · Betamethasone phosphate · Bupivacaine · Chloroquine · Dexamethasone · Flumethasone +4 more
  8. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    CG7870 is an oncolytic virus therapy for prostate cancer. … It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  9. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).

  10. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to … This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970.

    Categories: Antidepressive Agents Indicated for Depression